Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Adults |
Dose: Chewable Tablet – 2-4 tablets Note: The tablet must be chewed thoroughly before swallowing. |
|
Age: Adults |
Dose: Oral Liquid – 10-20 mL (two to four 5 mL spoonfuls) Note: None provided. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: greater than 12 years |
Dose: Chewable Tablet – 2-4 tablets Note: The tablet must be chewed thoroughly before swallowing |
|
Age: greater than 12 years |
Dose: Oral Liquid – 10-20 mL (two to four 5 mL spoonfuls) |
Administration
- Take as directed
- Take after meals for heartburn
Side Effect
- Gastrointestinal side effects have been reported the most frequently, These have included constipation (secondary to aluminum hydroxide therapy) and diarrhea (secondary to magnesium carbonate therapy)
- Patients with renal failure may be at risk of aluminum toxicity because of ingestion of aluminum hydroxide and because of exposure to aluminum-containing water used for dialysate solutions
- Adverse effects of aluminum accumulation in these patients has led to monitoring of water source aluminum content by dialysis units and periodic measurements of serum aluminum in patients undergoing chronic dialysis
- Concurrent administration of aluminum hydroxide with citrate containing products has been associated with unusually high serum concentrations of aluminum and especially in cases of renal failure, severe toxicity, Citrate may increase aluminum solubility and absorption
- During long-term use, aluminum has been shown to deposit in bone, joint and brain
- hypotension
- nausea
- vomiting
- EKG changes
- respiratory depression
- loss of deep tendon reflex
- dilated pupils
- altered mental status
- coma
- In patients on long-term aluminum hydroxide therapy
- especially in association with poor diets
- hypophosphatemia may result in muscle weakness
- rhabdomyolysis
- hemolysis
- and encephalopathy
- Osteomalacia due to aluminum deposition in bone is generally only seen in patients with chronic renal failure
- Bone formation slows in response to aluminum bone deposits
- Aluminum may also deposit in joint tissue, resulting in arthropathy and hydrarthrosis
- Musculoskeletal side effects have included osteomalacia due to aluminum hydroxide, which may occur by two different mechanisms
- Osteomalacia may occur due to hypophosphatemia or due to aluminum accumulation in bone
- Osteomalacia due to hypophosphatemia is often accompanied by malaise, bone pain, muscular weakness and bone fractures
- Osteomalacia due to aluminum deposition may present in a similar fashion and occurs predominately in patients with chronic renal failure
- Aluminum deposits typically can be observed on bone biopsy
- dysarthria
- dyspraxia
- dysphasia
- tremor
- myoclonus
- seizures
- coma
- and ultimately death
- EEG of patients with aluminum encephalopathy may show paroxysmal slowing and diffuse rhythmical bursts of delta activity
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
No interactions listed
|
-
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general drug reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Details coming soon
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.